低分子肝素钙、丁咯地尔联合应用治疗急性脑梗死的疗效观察

目的　观察低分子肝素钙、丁咯地尔联合应用对急性脑梗死的疗效。方法　 83例急性脑梗死患者随机分成 2组 ,治疗组 ( 4 9例 )用低分子肝素钙 0 .4ml,每 12小时脐周交替注射 1次 ,共用 7天 ;丁咯地尔注射液 15 0mg加入 5 %葡萄糖注射液静脉滴注 ,1次 天 ,共 15天。对照组 ( 34例 )应用蝮蛇抗栓酶 0 .75U加入 0 .9%盐水 2 5 0ml静滴 ,1次 天 ,共 15天。分别观察 2组治疗前后血液学改变及临床疗效。结果　治疗组凝血酶原时间、血小板、纤维蛋白原均较治疗前有明显改善 ,2组治疗后比较 ,治疗组凝血酶原时间、纤维蛋白原均比对照组有显著改善 (分别为P <0 .0 1、P <0 .0 5 )。治疗组总有效率及显效率分别为 93.9%、71.4 % ;对照组总有效率及显效率分别为 85 .3%、5 0 .0 % ,2组比较差异非常显著(P <0 .0 1)。 2组均未发现脑出血。结论　低分子肝素钙、丁咯地尔联合应用治疗急性脑梗死 ,其改善血液学及临床疗效方面均明显优于蝮蛇抗栓酶。且安全、疗效确切

The clinical observation of buflomedil hydrochloride combined with low-molecular-weight haparin calcium in treating acute cerebral infarction

Objective To investigate the therapeutic effect of buflomedil hydrochloride combined with low molecular weight haparin calcium on acute cerebral infraction.Methods 83 patients with acute cerebral infarction were randomly divided into two groups. 49 patients in treatment group were treated by 0.4ml low molecular weight haparin calcium, once per 12 hours, for a treatment course of 7 days,and buflomedil hydrochloride 150ml with 5% glucose, intravenous infusion once a day for 15 days. 34 patients in control group were treated by 0.75U ahlysantinfaretase with 0.9% normal saline 250 ml,intravenous infusion once a day for 15 days. The hematological changes and clinical effect were observed before and after treatment.Results The hematological changes including fibrinogen, platelets, prothrombin time were improved after treatment, and the changes of prothrombin time,fibrinogen in treatment group were superior to those of control group(P<0.01,P<0.05).The total effective rate and notable effective rate in treatment group were 92.3% and 69.2% respectively, and 83.0% and 48.8% in control group respectively. There was a significant difference between two groups (P<0.01).The hemorrhagic cerebral infarction was not found in both groups.Conclusion Buflomedil hydrochloride combined with low molecular weight haparin calcium is effective and safe in treating acute cerebral infarction, which is better than ahylysantinfaretase in clinical therapeutic effect and improvement of hematological parameters.